Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its programs center on CardiolRx™, an oral cannabidiol formulation, and CRD-38, a subcutaneously administered drug candidate, with development activity primarily in Canada and the United States.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaOral anti-inflammatory therapy being studied for cardiac inflammatory diseases such as myocarditis and pericarditis.
Clinical development program evaluating CardiolRx™ in acute myocarditis.
Clinical development program evaluating CardiolRx™ in recurrent pericarditis.
Subcutaneously administered drug formulation under development for cardiovascular inflammation and fibrosis.
Asiakkaat
Cardiol Therapeutics does not sell into a broad commercial customer base in the traditional sense; its primary counterparties are clinical trial investigators, research institutions, contract research organizations, and regulators involved in drug development. If and when its therapies reach commercialization, the ultimate end users would be patients with inflammatory heart disease and the physicians who treat them.
Hospitals and research centers that enroll patients into ARCHER and MavERIC because they enable the clinical evidence base.
Physicians and investigators who assess and treat myocarditis or pericarditis and help define clinical endpoints.
CROs, laboratories, and advisory providers that support trial operations, data collection, and regulatory documentation.
Patients with acute myocarditis or recurrent pericarditis who would ultimately use approved therapies.
Strategia
Cardiol’s strategy is to advance clinical evidence for its heart-disease programs through late-stage trials and expand its trial network to support enrollment. The company is positioning its platform around differentiated anti-inflammatory and anti-fibrotic mechanisms in diseases with limited approved treatment options, while maintaining optionality with a second formulation candidate in CRD-38.
Late-stage clinical data are the main driver of value in a development-stage biotech company.
Robust clinical evidence is required to support future regulatory filings and partnering discussions.
A second candidate can broaden the company's development base beyond one lead program.
Maantiede
The company is headquartered in Canada and reports to U.S. and Canadian capital markets, with corporate administration based in Oakville, Ontario. Its clinical development footprint is concentrated in North America, particularly the United States, where the MavERIC phase III network has been expanded, and Canada, where the company is domiciled and conducts corporate functions.
Riskit
Cardiol’s value creation depends on clinical success, so trial outcomes, enrollment speed, and regulatory feedback are the central risks. As a development-stage biotech, it also faces funding risk, dilution risk, and execution risk tied to outsourced research, manufacturing, and clinical operations.
- Clinical trial failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Lead programs depend on positive safety and efficacy data in small, specialized patient populations.
Kohdistuu - Enrollment and site activation delaysVaikutus: KorkeaTodennäköisyys: Korkea
Rare or acute cardiac conditions can be difficult to recruit and operationally complex to study.
Kohdistuu: U.S. trial network expansion
- Financing and dilutionVaikutus: KorkeaTodennäköisyys: Korkea
Development-stage biotech companies typically rely on external capital before commercialization.
Kohdistuu: Research and clinical development spend
- Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even positive trial data may not translate into approval if regulators request additional evidence.
Kohdistuu: Future filings and development milestones
Kirjanpito
Harkinnanvaraiset erätTrial and advisory services are recognized based on estimates of work completed before invoices are finalized.
Vaikutus: Can change quarterly R&D expense and liabilities
Equity awards to employees and directors are measured at fair value and expensed over vesting periods.
Vaikutus: Affects operating expense and earnings without cash outflow
The company disclosed advisory services from a director-related company, which requires careful disclosure and valuation.
Vaikutus: Can influence perceived governance and expense classification
Trial activity is uneven, so costs can be lumpy across quarters and affect comparability.
Vaikutus: Quarterly R&D volatility
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Milestone Pharmaceuticals Inc.
MIST · Pharmaceutical Preparations
BioCardia, Inc.
BCDA · Biological Products, (No Diagnostic Substances)
Acrivon Therapeutics, Inc.
ACRV · Pharmaceutical Preparations
Dogwood Therapeutics, Inc.
DWTX · Pharmaceutical Preparations
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Päivitetty: 28.9.2026